The evolving role of mycophenolate mofetil in renal transplantation

QJM: An International Journal of Medicine

Volumn 93, Issue 1, 2000, Pages 15-20

  Warrens, A N ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CREATININE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INOSINATE DEHYDROGENASE; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

BLOOD TOXICITY; CREATININE BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HUMAN; INFECTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0033979772     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/93.1.15     Document Type: Review

References (52)

1. Lipsky J. Mycophenolate mofetil. Lancet 1996; 348:1357-9.
2. Allison A, Eugui E. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 1993; 136:5-28.
3. Carr S, Papp E, Wu J, Natsumeda Y. Characterisation of human type I and type II IMP dehydrogenases. J Biol Chem 1993; 268:27286-90.
4. Eugui E, Almquist S, Muller C, Allison A. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991; 33:161-73.
5. Morris R, Wang J. Comparison of the immunosuppressive effects of mycophenolic acid and the morpholinoethyl ester of mycophenolic acid (RS-61443) in recipients of heart allografts. Transplant Proc 1991; 23:493-6.
6. Morris R, Hoyt E, Murphy M, Eugui E, Allison A. Mycophenolic acid morpholinoethyl ester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 1990; 22:1659-62.
7. Kawamura T, Hullett D, Suzuki Y, Bechstein W, Allison A, Sollinger H. Enhancement of allograft survival by combination RS-61443 and DUP-785 therapy. Transplantation 1993; 55:691-5.
8. Tanabe M, Todo S, Murase N, Irish W, Miyazawa H, Fujisaki S, Starzl T. Combined immunosuppressive therapy with low dose FK506 and antimetabolites in rat allogeneic heart transplantation. Transplantation 1994; 58:23-7.
9. Knechtle S, Wang J, Burlingham W, Beeskau M, Subramanian R, Sollinger H. The influence of RS-61443 on antibody-mediated rejection. Transplantation 1992; 53:699-701.
10. Bechstein W, Schilling M, Steele D, Hullett D, Sollinger H. RS-61443/cyclosporine combination therapy prolongs canine liver allograft survival. Transplant Proc 1993; 22:876-9.
11. Coulombe M, Hao L, Calcinaro F. Tolerance induction in adult animals: comparison of RS-61443 and anti-CD4 treatment. Transplant Proc 1991; 23:31-2.
12. Hao L, Lafferty K, Allison A, Eugui E. RS-61443 allows islet allografting and specific tolerance induction in adult mice. Transplant Proc 1990; 22:876-9.
13. Hao L, Calcinaro F, Lafferty K, Allison A, Eugui E. Tolerance induction in adult mice: cyclosporine inhibits RS-61443-induced tolerance. Transplant Proc 1991; 23:733-4.
14. Daloze P, Chen H, Qi S. Prolongation of pancreas allograft survival by RS-61443 in the rat. In: International congress on new immunosuppressive drugs. Montreal, Canada, 1995.
15. Platz K, Sollinger H, Hullett D, Eckhoff D, Eugui E, Allison A. R5-61443 - a new, potent immunosuppressive agent. Transplantation 1991; 51:27-31.
16. Platz K, Bechstein W, Eckhoff D, Suzuki Y, Sollinger H. RS-61443 reverses acute allograft rejection in dogs. Surgery 1991; 110:736-41.
17. Paul L, Zhang S, Valentin J, Bruijn L. Mycophenolate mofetil protects against ischemia-reperfusion induced graft failure. Nephrology 1997; 3(S1):S322.
18. Allison A, Eugui E. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996; 10:77-84.
19. Morris R, Wang J, Blum J, Flavin T, Murphy M, Almquist S, Chu N, Tam Y, Kaloostian M, Allison A. Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts. Transplant Proc 1991; 23:19-25.
20. O'Hair D, McManus R, Komorowski R. Inhibition of chronic vascular rejection in primate cardiac xenografts using mycophenolate mofetil. Ann Thorac Surg 1994; 58:1311-15.
21. Azuma H, Binder J, Heemann U, Schmid C, Tullius S, Tilney N. Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts. Transplantation 1995; 59:460-6.
22. Fujihara C, Malheiros D, Zatz R, Noronha I. Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 1998; 54:1510.
23. Oz H, Hughes W. Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus and dexamethasone. J Infect Dis 1997; 175:901-4.
24. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for the prevention of acute rejection. Lancet 1995; 345:1321-5.
25. The Tricontinental Mycophenolate Mofetil Renal transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61:1029-37.
26. Sollinger H, US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60:225-32.
27. O'Gara M, Lee C, Weinberg G, Nott J, Queener S. IMP dehydrogenase from Pneumocystis carinii as a potential drug target. Antimicrob Agents Chemother 1997; 41:40-8.
28. Tressler R, Garvin L, Slade D. Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo, Int J Cancer 1994; 57:568-73.
29. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients. Transplantation 1997; 63:39-47.
30. Miller J. Tacrolimus and mycophenolate mofetil in renal transplant recipients: six and twelve month recults of a multicenter, randomized dose ranging study. In: American Society of Transplant Physicians, 17th Annual Meeting. Chicago, 1998.
31. Neylan J. Immunosuppressive therapy in high-risk transplant patients. Dose-dependent effect of mycophenolate mofetil in African-American renal allograft recipients. Transplantation 1997; 64:1277-82.
32. Sollinger H, Deierhoi M, Belzer F, Diethelm A, Kauffman R. RS-61443 - a phase I clinical trial and pilot rescue study. Transplantation 1992; 53:428-32.
33. Deierhoi M, Kauffmann R, Hudson S, Barber W, Curtis J, Julian B, Gaston R, Laskow D, Diethelm A. Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center. Ann Surg 1993; 217:476-84.
34. The Mycophenolate Mofetil Renal Refractory Rejection Study Group. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. Transplantation 1996; 61:722-9.
35. The Mycophenolate Mofetil Acute Renal Rejection Study Group. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection. Transplantation 1998; 65:235-41.
36. Grinyo G, Gil-Vernet S, Seron D, Cruzado J, Moreso F, Fulladosa X, Castelao A, Torras J, Hooftman L, Alsina J. Steroid withdrawal in mycophenolate mofetil-treated renal allograft recipients. Transplantation 1997; 63:1688-90.
37. Ducloux D, Fournier V, Bresson Vautrin C, Rebibou JM, Billerey C, Saint Hillier Y, Chalopin JM. Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity: a preliminary report. Transplantation 1998; 65:1504-6.
38. Burke J, Islam M, Francos G, Dunn S. Introduction of mycophenolate mofetil (MMF) and reduction in cyclosporine (CyA) dosage is effective in the treatment of chronic renal allograft dysfunction. Nephrology 1997; 3(S1):S329.
39. Weir MR, Anderson L, Fink JC, Gabregiorgish K, Schweitzer EJ, Hoehn Saric E, Klassen DK, Cangro CB, Johnson LB, Kuo PC, Lim JY, Bartlett ST. A novel approach to the treatment of chronic allograft nephropathy. Transplantation 1997; 64:1706-10.
40. Grinyo JM, Gil Vernet S, Seron D, Cruzado JM, Moreso F, Fulladosa X, Castelao AM, Torras J, Hooftman L, Alsina J. Steroid withdrawal in mycophenolate mofetil-treated renal allograft recipients. Transplantation 1997; 63:1688-90.
41. Glicklich D, Gupta B, Schurter-Frey G, Greenstein S, Schechner R, Tellis V. Chronic renal allograft rejection - no response to mycophenolate mofetil. Transplantation 1998; 66:398-9.
42. Zanker B, Schneeberger H, Rothenpieler U, Hillebrand G, Illner W, Theodorakis I, Stnagle M, Land W. Mycophenolate mofetil-based, cyclosporine-free induction and maintenance immunosuppression - first three months analysis of efficacy and safety in two cohorts of renal allograft recipients. Transplantation 1998; 66:44-9.
43. Ferguson R. Acute rejection episodes - best predictor of long-term primary cadaveric transplant survival. Clin Transplant 1994; 8:328-31.
44. Gulanikar AC, MacDonald AS, Sungurtekin U, Belitsky P. The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants. Transplantation 1996; 53:323-8.
45. Cecka J. Early rejection: determining the fate of renal transplants. Transplant Proc 1991; 23:1263.
46. Naimark D, Cole E. Determinants of long-term renal allograft survival. Transplant Rev 1994; 8:93.
47. Basadonna G, Matas A, Gillingham K, Payne W, Dunn D, Sutherland D, Gores P, Gruessner R, Najarian J. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993; 55:993-5.
48. Matas A, Gillingham K, Payne W, Najarian J. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 1994; 57:857-9.
49. Vereerstraeten P, Abramowicz D, de Pauw L, Kinnaert P. Absence of deleterious effect on long-term kidney graft survival of rejection episodes with complete functional recovery. Transplantation 1997; 63:1739-43.
50. Tomlanovich S, Cho S, Hodge E, Miller J, Neylan J, Hooftman L, Rees M. Mycophenolate mofetil in cadaveric renal transplantation: 3-year data. In: American Society of Transplant Physicians 16th Annual Meeting. Chicago, 1997.
51. Pichlmayr R, Vanrenterghem Y, Groth C, Grinyo J, Hooftman L, Wang W. European mycophenolate mofetil trial: 3-year results. In: European Society of Transplantation Florence, 1997.
52. Mathew T. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation - results at three years. Transplantation 1998; 65:1450-4.